Cross-disease multi-modality mapping of the human lung
Active Cooperative Agreement Awarded Last action
- Award ID
- U01HL175452
- Recipient
-
University Of California, San Diego UEI UYTTZT6G9DT1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,218,284
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 43% complete
- Place of performance
- La Jolla, CA 92093, USA
Award details come from USAspending.gov.
Description
- Abstract
- The tremendous diversity across human lung diseases presents significant clinical challenges, but also offers remarkable opportunities for capturing high-resolution disease mechanisms to more effectively treat these conditions. Adhering to the mission of lungmap phase II, our research center has generated, curated, and made publicly available a rich array of high-quality single nucleus rnaseq and single nucleus atacseq datasets, focusing on normal developing lung and pediatric lung diseases. In lungmap phase III, with the extension into adult lung diseases, we will leverage our expertise on lung biology and single cell technologies to embark on direct cross-disease comparisons, a recognized bottleneck in the next-stage disease mechanism discoveries. We have assembled an interdisciplinary team with strong expertise in lung biology, pulmonology, surgery, pathology, single cell technology and computational biology, with a track record of working together within and beyond the lungmap consortium. Guided by the scientific premise that different lung diseases can be distinguished by a finite set of signatures, we will test the hypothesis that these diseases differ in cell type/cell state composition, transcriptomic and epigenomic profiles, signaling and extracellular matrix dynamics, among other dimensions. Capturing cutting-edge technologies, we present robust preliminary data demonstrating the feasibility of using single nucleus multiome (rnaseq and atacseq from the same nucleus) and spatial transcriptomic merfish (multiplexed error-robust fluorescence in situ hybridization) technologies on tissues procured using an ultra-low ischemia time protocol. Critical to achieving precise cross- disease comparisons, we show preliminary data demonstrating effective addition of multiplexing to these technologies, which eliminated batch effect which was the major roadblock in previous comparison efforts. We expect that the datasets that we will generate and make publicly available in lungmap phase III will facilitate paradigm-shifting studies by the collective lung research community.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $727,022 | |
| Amendment | $743,401 | |
| Original award | $747,861 |
Quick answers
Who received award U01HL175452?
U01HL175452 was awarded to University Of California, San Diego by National Heart Lung and Blood Institute (National Institutes of Health) on September 1, 2024.
How much is award U01HL175452 worth?
$2,218,284 has been obligated on U01HL175452.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award